Mitosis as an anti-cancer drug target

被引：0
|
作者：
Anna-Leena Salmela
Marko J. Kallio
机构：
[1] VTT Technical Research Centre of Finland,VTT Biotechnology for Health and Wellbeing
来源：
Chromosoma | 2013年 / 122卷
关键词：
Anti-mitotics; LMW inhibitors; Mitosis; Cancer; Drug development;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.
引用
收藏
页码：431 / 449
页数：18
相关论文
共 50 条
  • [41] Cancer stem cell: target for anti-cancer therapy
    Tang, Carol
    Ang, Beng T.
    Pervaiz, Shazib
    [J]. FASEB JOURNAL, 2007, 21 (14): : 3777 - 3785
  • [42] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
    Shoyo Shibata
    Maiko Matsushita
    Yoshimasa Saito
    Takeshi Suzuki
    [J]. Therapeutic Innovation & Regulatory Science, 2018, 52 : 442 - 448
  • [43] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
    Shibata, Shoyo
    Matsushita, Maiko
    Saito, Yoshimasa
    Suzuki, Takeshi
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (04) : 442 - 448
  • [44] Nuclear assembly as a target for anti-cancer therapies
    Gorjanacz, Matyas
    [J]. NUCLEUS, 2014, 5 (01) : 47 - 55
  • [45] A screen to identify drug resistant variants to target-directed anti-cancer agents
    Mohammad Azam
    Tal Raz
    Valentina Nardi
    Sarah L. Opitz
    George Q. Daley
    [J]. Biological Procedures Online, 2003, 5 (1) : 204 - 210
  • [46] Hsp90 as an anti-cancer target
    Neckers, L
    Mimnaugh, E
    Schulte, TW
    [J]. DRUG RESISTANCE UPDATES, 1999, 2 (03) : 165 - 172
  • [47] Survivin: A new target for anti-cancer therapy
    Ryan, Brid M.
    O'Donovan, Norma
    Duffy, Michael J.
    [J]. CANCER TREATMENT REVIEWS, 2009, 35 (07) : 553 - 562
  • [48] Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
    Kobetl, Robert A.
    Pan, Xiaoping
    Zhang, Baohong
    Pak, Stephen C.
    Asch, Adam S.
    Lee, Myon-Hee
    [J]. BIOMOLECULES & THERAPEUTICS, 2014, 22 (05) : 371 - 383
  • [49] Erratum to: Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target
    Siva Kumar Kolluri
    Un-Ho Jin
    Stephen Safe
    [J]. Archives of Toxicology, 2017, 91 : 3209 - 3209
  • [50] Geranylgeranyltransferase I as a target for anti-cancer drugs
    Philips, Mark R.
    Cox, Adrienne D.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05): : 1223 - 1225
12345